Purified murine colony-stimulating factors (CSF) recombinant interleukin 3 (IL-3), natural CSF-1, and recombinant granulocyte-macrophage (GM) CSF were assessed in vivo for their ef-
Introduction
Colony-stimulating factors (CSF)' were originally defined based on their capacity to stimulate colony formation by hematopoietic These studies were presented at the 27th Annual Meeting ofthe American Society of Hematology, New Orleans, LA Hematol. 14:418).
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1. Abbreviations used in this paper: BFU-E, burst-forming unit, erythroid; BPA, burst-promoting activity; CFU-GEMM, colony-forming unit, granulocyte-erythroid-macrophage-megakaryocyte; CFU-GM, colonyforming unit, granulocyte-macrophage; CM, conditioned medium; CSF, colony-stimulating factor; CSF-1, macrophage CSF; GM-CSF, granulocyte-macrophage CSF; 3HTdR, tritiated thymidine; IL-3, interleukin 3; LF, lactoferrin; LPS, lipopolysaccharide; PWMSCM, pokeweed mitogen mouse spleen cell CM. progenitor cells in semisolid culture medium (1, 2) . Included in this group of factors are interleukin 3 (IL-3), also referred to as multi-CSF, CSF-2a, P-cell-stimulating factor, hemopoietin-2, burst promoting activity (BPA), 20a hydroxysteroid-inducing activity, WEHI-3 growth factor, Thy-l-inducing activity, colonyforming unit-spleen-stimulating activity, and hematopoietic cell growth factor), macrophage CSF (CSF-1), granulocyte-macrophage (GM)-CSF, and granulocyte (G)-CSF (1, 2) . IL-3 (3-6), pluripotent CSF (7) , pluripoietin a (8) , CSF-1 (9) (10) (11) (12) , GM-CSF (5, 13) , and G-CSF (14) have been purified to homogeneity, and more recently the complementary DNA (cDNA) and/or genes for IL-3 (15-18), CSF-1 (19) , GM-CSF (20-23), and G-CSF/ pluripotent CSF (24, 25) have been cloned and expressed. The receptors and receptor-binding for IL-3 (26-28), CSF-1 (27, [29] [30] [31] [32] [33] [34] [35] [36] , GM-CSF (27, [37] [38] [39] , and G-CSF (27, 40) have been studied and it is clear that in addition to their effects on hematopoietic progenitor cells (1, 2) , they also influence the functioning of more mature cells (reviewed in references 41 and 42; 43-48) . The possible involvement of the genes for some of these factors and their receptors in myeloid disorders has been suggested (49, 50) . Although there is now a wealth of information on the actions of these molecules in vitro, a paucity of information is available describing an activity for these purified molecules in vivo. The reports published are only for IL-3 and GM-CSF using mainly multiple or continuous infusions of high concentrations ofthese factors (5 1-54) . The present studies were undertaken to compare the short term effects in vivo of relatively low concentrations of purified preparations of recombinant murine IL-3, natural murine CSF-1, and recombinant murine GM-CSF on the numbers of nu-a-factor promoter and leader sequence to direct secretion of the mature forms of the factors (28, 38) . The expressed IL-3 and GM-CSF were purified using reversed-phase high-performance liquid chromatography. IL-3 had a specific activity of 109 U/mg protein when titered against the IL-3-dependent murine cell line FDC-P2 (28) . Units of IL-3 were determined as the reciprocal dilution of a sample that generated 50% of maximal FDC-P2 ['Hlthymidine incorporation as compared with a laboratory standard (WEHI-3b cell line conditioned medium). Therefore, if a sample stimulated 50% of maximal FDC-P2 ['H]thymidine incorporation at a dilution of 1:10, 10% of 100 ul (assay volume) or 10 ul contained I U. GM-CSF had a specific activity of 108 U/mg protein based upon mouse bone marrow colony formation (38) . Units of GM-CSF were determined using 10' mouse marrow cells in I ml and finding the dilution of sample which gave 50% maximal colony numbers. The 50% maximal number of colonies was then multiplied by the reciprocal of the sample dilution to yield number of CFU-GM per milliliter. L-cell CSF (CSF-l) was produced by the growth of murine L-cells in serumfree CMRL 1066 medium as described previously (10 (60) . Injections of factors to mice were in a volume of 0.2 ml. By using the Limulus lysate test for endotoxin, which has a sensitivity range down to 0.5 ng/ml, we detected no endotoxin (< 0.1 ng/ml) in the preparations of IL-3, GM-CSF, CSF-1, or LF. E. coli lipopolysaccharide was purchased from Sigma Chemical Co. Analysis ofhematopoietic progenitor cells in vitro. The assay for CFU-GM was performed as described (65) with the purified preparations of recombinant IL-3, natural CSF-1, recombinant GM-CSF and pokeweed mitogen mouse spleen cell conditioned medium (PWMSCM) as sources of CSF (65). Granulocyte-macrophage colony formation (> 50 cells/ aggregate) from cells taken from mice pretreated with the purified preparation of CSF and/or LF, was evaluated using 10% vol/vol PWMSCM as a stimulus. Clusters (3-50 cells) were scored also. As the results for colonies and clusters were similar to those for colonies, the results are only shown for colonies. Bone marrow and spleen cells were plated respectively at 7.5 X 104 and 1.0 X 106 cells/ml in 0.3% agar culture medium (Difco Laboratories Inc., Detroit, MI) that included McCoy's 5A medium supplemented with essential and nonessential amino acids, glutamine, serine, asparagine, and sodium pyruvate (Gibco Laboratories, Grand Island, NY), with 10% prescreened heat-inactivated (56°C for 0.5 h) fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT). Unless otherwise noted, colonies were scored after 6-7 d of incubation.
For colony morphology, agar cultures were overlaid with 1 ml of 0.5% glutaraldehyde (Sigma Chemical Co.) in 0.1 M phosphate buffer.
After 6 min, glutaraldehyde was removed and 2 ml absolute methanol was added to the plates. After the methanol evaporated (12-18 h ) the fixed cultures were submerged in distilled water. After rehydration, the agar pellicles were floated onto clean glass slides and allowed to dry. For identification ofgranulocytes and monocytes/macrophages, colonies were stained for 45 min with -naphthyl acetate esterase (Sigma Kit #90-Al) and counterstained with Mayer's hematoxylin for 10 min. Slides were washed, dried at room temperature, mounted (Permount, Fisher Scientific Co., St. Louis, MO), and scored at 400 X. Monocytes/macrophages were enumerated based on their morphology and the characteristic black cytoplasmic granulation.
The assay for BFU-E-2 was plated at 1 X 105 cells/ml for marrow and 1 X 106 cells/ml for spleen in a 1-ml mixture of Iscove's modified Dulbecco's medium (Gibco Laboratories), 0.8% methylcellulose, 30% prescreened FBS (HyClone Laboratories), 5 X 10-i M 2-mercaptoethanol, 1 U oferythropoietin (HyClone Laboratories) and 0.1 mM Hemin (Eastman Kodak Co., Rochester, NY). Hemin increases colony formation by BFU-E and CFU-GEMM (66) . BFU-E-l and CFU-GEMM assays were scored from the same plates and were set up as for BFU-E-2 except that 1% v/v PWMSCM was added. Cells were plated at 7.5 X 104 cells/ml for bone marrow and 1 X 106 cells/ml for spleen BFU-E-I and CFU-GEMM assays. BFU-E-2, BFU-E-1, and CFU-GEMM assays were scored after 6-7 d of incubation. BFU-E-2 colonies contained at least 50 cells or were composed of at least three subcolonies containing a minimum of 10 cells each, whereas colonies derived from BFU-E-I were much larger than those derived from BFU-E-2. BFU-E-I may represent a more immature progenitor than BFU-E-2, although this has not been proven. Cells were incubated in a humidified environment at lowered (5%) oxygen tension. Low oxygen tension was maintained using an Oxyreducer (Reming Bioinstruments, Rochester, NY) because lowered oxygen tension increases the incidence ofcolonies derived from hematopoietic progenitor cells (67) .
Cycle status ofhematopoietic progenitor cells. To estimate the proportion of progenitors in DNA synthesis (S-phase), cells were treated with either McCoy's medium or 50 ,Ci/ml tritiated thymidine ('HTdR) diluted in McCoy's medium (New England Nuclear, Boston, MA, specific activity, 20 Ci/mmol). After a 20-min incubation at 37°C, the cells were washed once in phosphate-buffered saline containing ice cold thymidine (2,000 Mg), twice more in McCoy's medium, and then plated into the CFIJ-GM, BFU-E, and CFU-GEMM assays. The reduction in the number of colonies after exposure of cells to 'HTdR compared with control (McCoy's medium) estimates the proportion of progenitor cells in cycle just before assaying for colony formation. The results are given as the percent ofcells in S-phase. A negative number means that more colonies formed after cells were exposed to tritiated thymidine than after cells were exposed to McCoy's medium. In some select cases, cells were also exposed to 500 ug thymidine, or 50 MCi 3HTdR plus 500 Mg thymidine as controls for the S-phase specificity of the treatments. In all cases, the numbers of colonies formed were statistically similar whether cells were exposed to McCoy's medium, thymidine, or 'HTdR plus thymidine.
The percentage of cells in S-phase was based on control colony counts that were in the range of 30-165, 15-39, 20-45, and 15-36, respectively for the CFUJ-GM, BFUJ-E-2, BFUJ-E-I, and CFUJ-GEMM assays.
Experimental protocols. The details ofthese are described in the results section and in the tables. After sacrifice, the marrow from the two femurs of each mouse was pooled. This marrow and the spleen of each mouse were assayed separately. Cells from different mice were not pooled. Three to four mice per group were used in each experiment unless otherwise noted in the text or in the table legends.
Statistical analysis. Three plates were scored for each CFUJ-GM sample and two plates were scored for each BFU-E-2 or BFUJ-E-I/CFLJ-GEMM sample. The results are expressed as the mean± I SEM and these are derived from the averages of the colony counts from each of the individual mice within a group. The probability ofsignificant differences between groups or samples was determined with the use of Student's t test.
Results
Influence ofcolony-stimulating factors in vitro. Before assessing the actions of IL-3, CSF-1, and GM-CSF in vivo, these growth factors were compared for their capacity to stimulate colony formation by bone marrow CFU-GM, BFU-E-1, and CFU-GEMM (Table I) . IL-3 contained GM-CSF, BPA, and multi-CSF activities, but the GM-CSF activity in the IL-3 preparation was relatively low compared with the other activities on a unit basis. Both CSF-l and GM-CSF-stimulated colony formation BDF1 bone marrow cells were plated at 7.5 X 104/ml and scored after 7 d of incubation at 5% 02 and 5% CO2. BFU-E and CFU-GEMM assays were plated in presence of 1 U erythropoietin and 0.1 mM hemin. Units of activity for the purified preparations of IL-3, GM-CSF, and CSF-1 were derived as described elsewhere (11, 28, 38) . Differences between the units quoted above and the actual numbers of CFU-GM colonies stimulated most likely reflect different culture conditions between laboratories and the use of marrow cells from different strains of mice. TNC, too numerous to count.
of CFU-GM, but neither contained BPA or mixed colony activities at concentrations that were plateau for stimulation of CFU-GM. IL-3 and GM-CSF-stimulated colony and cluster formation ofgranulocytes, macrophages, and granulocytes plus macrophages after 4 and 7 d of incubation (data not shown). While CSF-1 stimulated mainly macrophage colonies after 7 d ofincubation, colonies ofgranulocytes, macrophages, and granulocytes plus macrophages were stimulated by CSF-1 when colonies were scored after 4 d of incubation (Table II) . The results shown in Tables I and II have been reproduced in at least three different experiments. Effects ofIL-3 in vivo. IL-3 was assessed for effects on the cycling status ofbone marrow CFU-GM in mice pretreated with sterile pyrogen-free saline or with endotoxin-depleted iron-saturated human LF. Mice were given saline or 100 ,g LF i.v. and were inoculated i.v. 15 h later with 500 U IL-3 or control diluent. The cycling status ofcontrol mice given saline and control diluent was similar to that of mice not previously injected with any material (30-40% of CFU-GM in S-phase). In two separate experiments, LF significantly decreased (P < 0.0001) the percent of CFU-GM in S-phase from 31±4 and 30±5% to 4±9 and -4±2%. IL-3 significantly increased (P < 0.005) the percent of CFU-GM in S-phase to 59±4 and 54±4% in mice pretreated with saline. The stimulatory effect of IL-3 was even more apparent when the percent of CFU-GM in S-phase in mice given both LF and IL-3 (51±2 and 52±6%) was compared with the percent of CFU-GM in S-phase in mice given LF and then control diluent (4±9 and -4±2%).
Since LF decreases the cycling status and absolute numbers of marrow CFU-GM, BFU-E, and CFU-GEMM when administered to mice (55, 61, 62) , and pretreatment of mice with LF resulted in a more sensitive assay for detection of the effects of IL-3 in vivo, the rest of the studies with IL-3 were done by evaluating the effects of IL-3 in mice pretreated with 50 ,gg LF, which was as effective as 100 ,ug LF (data not shown). In LFpretreated mice, 500 U IL-3 increased the cycling status ofbone marrow CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM within 3 h ofIL-3 administration (Table III) . This effect was still apparent after 24 h, but was decreased substantially by 48 h (Table III) . IL-3 (500 U) increased the absolute numbers of BFU-E and CFU-GEMM, but not CFU-GM, within 24-48 h, with no significant effect within 3-48 h noted on the total nucleated marrow cell population (Table III) .
A dose response study of IL-3 on marrow (Table IV) and splenic (Table V) hematopoiesis within 22 h, after IL-3 administration to LF-pretreated mice, demonstrated that 2,000 U of IL-3 increased the absolute numbers and cycling status of both femoral and splenic CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM, without a detectable effect on the total nucleated cellularity of these organs (Tables IV and V) mice with LF also made them more sensitive to the effects of CSF-1, mice were given sterile pyrogen-free saline or 100 ,ug LF i.v. and were injected i.v. 15 h later with 20,000 U CSF-l or control diluent. Mice were sacrificed 3 h later. In two experiments, LF significantly decreased (P < 0.001) the percent of marrow CFU-GM in S-phase from 35±5% and 40±2% to -2± 10% and -8±4%. CSF-1 significantly increased (P < 0.005) the percent ofCFU-GM in S-phase to 66±4 and 61±2% in mice pretreated with saline. The stimulating effect ofCSF-1 was even more apparent when the percent ofCFU-GM in S-phase in mice given both LF and CSF-1 (62±10% and 63±8%) was compared to the percent of CFU-GM in S-phase in mice given LF and then control diluent (-2±10% and -8±4%).
A time sequence study evaluating the effects of CSF-1 in LF-pretreated mice (Table VI , experiments 1-4) demonstrated that 20,000 U of CSF-1 increased the cycling status of bone marrow CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM within 3 h, with this increase still apparent after 12 and 24 h. By 48 h, the cycle enhancing effects of CSF-l were no longer apparent. CSF-1 caused increases in the absolute numbers of these progenitors by 12-24 h with no detectable effect apparent by 48 h. Because the suppressive effects of LF in vivo are lost with time (60), mice were given sequential treatments with LF and CSF-l (Table VI, experiment 5) and the mice were evaluated 24 h after the second injection with CSF-1, which was 39 h after the first administration of CSF-1. These mice received a total dosage of 100Mgg LF and 40,000 U CSF-1. Under these conditions both the cycling status and absolute numbers of marrow progenitors were enhanced significantly. No significant effect on total nucleated cellularity was apparent in the five separate experiments shown in Table VI .
By assessing the marrow and splenic effects of varying concentrations of CSF-1 given to mice pretreated with LF (Tables   VII and VIII) it was apparent that CSF-1, at concentrations of 10,000 and 20,000 U, significantly increased the percent ofmarrow and splenic CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM that were in S-phase. CFU-GM were more sensitive to the effects ofCSF-I than were BFU-E and CFU-GEMM ( Tables   Table IV Mice were pretreated with 50 yg endotoxin-depleted human lactoferrin i.v. 3 h later they were treated with control medium or various concentrations of IL-3. Mice were sacrificed 22 h later. Results are the average of six mice (in a total of two experiments). Numbers in parentheses designate the percent (%A) from control. * P < 0.05 compared with control medium. * P < 0.005 compared with control medium.
VII and VIII) and the marrow progenitors (Table VII) were more sensitive than the splenic progenitors (Table VIII) to the enhancing effects of CSF-1. These experiments (Tables VII and  VIII) were performed differently from those reported in Table  VI in that the growth factor was given to mice 3 h, rather than 12 h, after the LF inoculation. Under these conditions a significant increase in the numbers ofbone marrow CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM was only detected in one of these three experiments using 20,000 U of CSF-1 (data not shown in the cycling status of marrow CFU-GM (54±1% and 57±3% in S-phase) when compared with the cycling status of CFU-GM (34±4% and 44±3% in S-phase) in mice given control diluent. No significant effect was detected on the cycling status of BFU-E-2 in these mice with 18±5% and 12±5% of cells in S-phase in mice given GM-CSF compared with 13±4% and 7±2% of cells in S-phase in mice receiving control diluent. In these mice, GM-CSF had no effect on the total nucleated cellularity or on the absolute number of CFU-GM and BFU-E-2 in the marrow. Because the effects ofGM-CSF given to previously untreated mice were only minimal, and based on the experience using LF-pretreated mice as a more sensitive assay to detect the stimulating effects in vivo of IL-3 and CSF-1, the effects of varying concentrations of GM-CSF were evaluated on marrow and splenic nucleated cellularity, numbers ofprogenitors per organ and on the Tables IX and X. GM-CSF increased the percent of marrow and splenic CFU-GM and CFU-GEMM in S-phase, but had no significant effect on the cycling status of BFIJ-E-2 and BFU-E-1. The cycling status of CFU-GM was more sensitive to the enhancing effects of GM-CSF than was the cycling status ofCFU-GEMM and at least for CFU-GEMM, the marrow appeared to be a more sensitive organ than the spleen to these effects. Not shown is that concentrations of 1,250-20,000 U of GM-CSF had no significant effect on the nucleated cellularity, on numbers ofCFU-GM, BFU-E-2, BFU-E, or CFU-GEMM per femur or spleen, or on peripheral blood counts.
Comparative effects ofIL-3, CSF-1, and bacterial lipopolysaccharide (LPS) in vivo in mice pretreated with LF. No contamination of endotoxin could be detected in the CSF samples 
Mice were pretreated with 50 ,g endotoxin-depleted iron-saturated human lactoferrin i.v., given control diluent or GM-CSF i.v. 3 h later and sacrificed 24 h later. Results are for three mice per group (one experiment). * Significant change from mice given control diluent, P < 0.005. Other changes are not significant, P > 0.05. the effects of IL-3 than was the CFU-GM compartment. This correlated well with the actions of the preparation in vitro. In contrast, CSF-1, while manifesting effects on these same progenitor cells, appeared to be a more effective stimulator at lower concentrations for CFU-GM than for BFU-E and CFU-GEMM. GM-CSF was more effective in stimulating CFU-GM than CFU-GEMM, and had no influence on the BFU-E compartments.
Of potential physiological relevance is that the enhancement of (45) , acidic isoferritins (41), interferon-alpha (44, 46) , and tumor necrosis factor (46) . Thus the possibility existed that stimulating effects-ofCSF in vivo might be masked by suppressor molecules induced by the CSF. Since LF suppresses release of PGE (45) and acidic isoferritins (41) from monocytes and macrophages in vitro, it was possible that LF could decrease the CSF-induced release of suppressor molecules in addition to decreasing the endogenous production/release of growth factors.
Endotoxins cause a number ofhematopoietic effects in vivo, including increased release of colony-stimulating activities, and enhanced myelopoiesis due to increased blood cell production and increased release of granulocytes from the marrow granulocyte reserve (56, 63, 70) . For this reason we carefulty controlled for the potential effects of contaminating endotoxin. Our preparations of CSF did not contain endotoxin, at least within the sensitivity of the Limulus lysate test, and the effects of IL-3, CSF-1, and GM-CSF in vivo were not mimicked by concentrations of 0.1-100 ng E. coli LPS. Full dose response curves were done with LPS because LPS can have both stimulating and suppressing activities that can be related to the concentrations of LPS used. Further evidence against CSF effects being due to contamination ofendotoxin is that the preparations of CSF had no effect on the circulating levels of granulocytes, monocytes, or lymphocytes within 3 to 48 h after administration of the CSF to previously untreated mice (data not shown). Of interest to the relative inactivity of LPS in these mice is that they were pretreated with LF. LF counteracts the release of CSF induced by LPS in vitro, but this depends on the relative concentrations of LPS to LF present in the culture (55, 56 (51) (52) (53) , however C3H/HEJ mice are less sensitive, but not resistant, to the effects of LPS (56).
Our studies do not allow us to conclude whether the effects of IL-3, CSF-1, and GM-CSF in vivo are direct ones on the hematopoietic progenitors in the marrow and spleen, whether these effects are mediated through an action on accessory cells present in the blood, marrow, or spleen, or if the actions are both direct and indirect. It is possible that at least some of the effects of IL-3 noted in vivo are direct ones on the progenitors. CSF-l stimulates macrophage progenitors directly (71) , and in an unseparated population of marrow cells it stimulates colonies of granulocytes and granulocytes plus macrophages, as well as macrophages (Table II) , but there is no evidence that CSF-l can act as a BPA or multi-CSF in vitro (Table I) . GM-CSF, in addition to its direct effect on CFU-GM in vitro (71) , has a proliferative effect on CFU-GEMM and BFU-E (72) and there are reports that GM-CSF may be a multi-CSF (73) . However, this latter report was based on experiments using enriched but not pure populations of progenitors, and it is still possible that these effects were indirect. Using an unseparated population ofmarrow cells, we could not detect BPA or multi-CSF activity in our preparation of recombinant GM-CSF at concentrations up to those stimulating plateau levels ofgranulocyte and macrophage colony formation. These results are consistent with recent reports from two other groups using recombinant murine GM-CSF (74, 75) . There are reports ofCSF preparations stimulating the release ofother types ofCSF from cells in vitro (46) (47) (48) , and it is probable that at least some of the effects in vivo of IL-3, CSF-1, and GM-CSF are mediated through the induced release of other growth factors for hematopoietic stem and progenitor cells.
Our studies were designed to study only the short term effects of relatively low concentrations of IL-3, CSF-1, and GM-CSF in vivo. During the time periods evaluated (up to 48 h) and under the conditions of our experiments, we did not detect any effect on total marrow or splenic nucleated cells or on circulating levels or differentials ofblood cells. The inability to detect changes in the mature myeloid blood cell compartments may be a manifestation of the short period of evaluation, the need for higher concentrations of factors, multiple factors, and/or multiple additions ofone or more factors, including those that may be more involved in differentiation as compared with proliferation.
